JAIDS Journal of Acquired Immune Deficiency Syndromes:
Letter to the Editor
Increased Plasma CXCL10 May be a Marker of Increased Risk of Immune Restoration Disease Associated With Nonviral Pathogens
Oliver, Benjamin G. BSc(Hons)*; Price, Patricia MSc, PhD*; Wand, Handan MA, MSc, PhD†; French, Martyn A. MB, ChB, MD*
*School of Pathology and Laboratory Medicine, University of Western Australia, Perth, Australia
†Biostatistics and Databases Program, Kirby Institute, University of New South Wales, Sydney, Australia
Correspondence to: Martyn A. French, MB, ChB, MD, Winthrop Professor, School of Pathology and Laboratory Medicine, University of Western Australia, 35 Stirling Hwy, Crawley WA 6009, Australia (e-mail: firstname.lastname@example.org).
Supported by the Medical Research Council (United Kingdom) and Bristol-Myers Squibb.
The authors have no conflicts of interest to disclose.
To the Editors:
Commencement of antiretroviral therapy (ART) in HIV patients with a recently treated or unrecognised opportunistic infection may result in immune restoration disease (IRD) in those patients who experience the restoration of a pathogen-specific immune response that causes immunopathology.1 The immunopathology may be different for different pathogens.2 Plasma biomarkers which may predict some forms of IRD have been identified,3–7 but knowledge remains incomplete. We have undertaken further studies using plasma samples from patients enrolled into the INITIO study.
The INITIO study was a large international randomized trial of ART treatment strategies in ART-naive HIV patients who were allocated 2 nucleoside analogue reverse transcriptase inhibitors (didanosine and stavudine) with either a nonnucleoside reverse transcriptase inhibitor (efavirenz) or a protease inhibitor (nelfinavir) or both.8
Here, we examined levels of proinflammatory cytokines/chemokines and other markers of immune activation (IL-6, IL-18, soluble(s) CD8, sCD26, sCD30, CXCL10, and vascular endothelial growth factor) in plasma samples collected before ART from patients recruited to the INITIO study who experienced IRD and matched controls. We considered if these markers might reveal more about the prediction of IRD.
Forty-three patients who had an infectious disease event during the first 24 weeks of ART were identified from the INITIO database. Twenty-four of these patients were classified as having probable IRD because the plasma HIV RNA level had declined by >1 log10, and the infectious disease event had occurred during the first 12 weeks of ART.9 As the number of patients experiencing IRD with individual pathogens was small, levels of plasma biomarkers were compared in patients classified as having “viral IRD” only (Kaposi sarcoma: n = 4, cytomegalovirus disease: n = 2, herpes simplex virus disease: n = 1, progressive multifocal leucoencephalopathy [PML]: n = 1, lymphoma: n = 1) or “nonviral IRD” only (Mycobacterium avium complex disease: n = 3, Toxoplasma gondii disease: n = 2, Pneumocystis carinii pneumonitis: n = 2, Cryptococcal meningitis: n = 1, Mycobacterium tuberculosis disease: n = 1, Mycobacterium avium complex disease and Candidiasis: n = 1) and matched controls. Each IRD patient was matched with 2 non-IRD controls by sex, pre-ART CD4+ T-cell count and country of origin where possible. For 6 “nonviral IRD” cases, samples were available from only 1 control. The median time of IRD onset was 6.5 weeks after the start of ART (range: 1–24 weeks). All patients provided written and informed consent.
Plasma levels of IL-6, CXCL10, and vascular endothelial growth factor were measured using BD Cytometric Bead Array Flex Sets (BD Biosciences, San Jose, CA). Three hundred events were collected per analyte using a BD FACSArray machine and BD FACSArray System Software v1.0.3 (BD Immunocytometry Systems, San Jose, CA). Analysis was performed using FCAP Array Software v1.0.1 (BD Biosciences). All samples were diluted 1/5. The lowest limit of detection was 5 pg/mL. Plasma levels of IL-18 (MBL, International, Woburn, MA) and sCD30 (Bender Medsystems; Vienna, Austria) were measured by enzyme-linked immunosorbent assay. Levels of sCD26 were measured by an enzyme capture assay.10 Soluble CD8, a marker of CD8+ T-cell activation, was assayed in the plasma of patients who developed IRD associated with cytomegalovirus and JC virus (PML) infection and matched controls using an enzyme-linked immunosorbent assay (Bender Medsystems). Pre-ART levels of immune markers in IRD and non-IRD patients were compared using the Mann–Whitney U test. Statistical significance was defined as P < 0.05.
Age, sex, pre-ART CD4+ T cell count, HIV RNA load, smoking status, and treatment arm were similar in IRD cases and controls (data not shown). Plasma levels of IL-6 and sCD8 were below the lower limit of detection of the assay (<5 pg/mL and <15.6 U/mL, respectively). Plasma levels of IL-18, sCD26, sCD30, and CXCL10 were similar in IRD cases and controls pre-ART when all cases of IRD were considered together (P = 0.18–0.76; data not shown). However, pre-ART levels of CXCL10 were significantly higher in “non-viral IRD” cases when compared with matched controls (P = 0.008) (Fig. 1). Pre-ART levels of CXCL10 did not differ between “viral IRD” cases and controls (P = 0.74) or between “nonviral IRD” cases and “viral IRD” cases (P = 0.21) (Fig. 1). Pre-ART plasma levels of IL-18, sCD26, and sCD30 did not differ between “nonviral IRD” cases and controls (P = 0.56–0.90; data not shown), “viral IRD” cases and controls or between “nonviral IRD” and “viral IRD” cases (P = 0.14–0.82; data not shown).
We have previously shown that increased plasma levels of CXCL10 are associated with IRD in HIV patients with Hepatitis B virus or M. tuberculosis infection and might therefore be a marker of disease immunopathogenesis.4,11 Pre-ART levels of CXCL10 in plasma from unstimulated whole blood cultures were predictive of “paradoxical” TB-IRIS4 and pre-ART CXCL10 responses to region of difference 1 (RD1) antigens of M. tuberculosis were predictive of TB-IRIS and ART-associated tuberculosis (ART-TB; most cases of which are equivalent to “unmasking” TB-IRIS) (Oliver B, BSc, unpublished data, December 2011). Here, pre-ART plasma levels of CXCL10 were higher in patients who subsequently developed a “nonviral IRD” in contrast to matched controls and patients with “viral IRD”. Increased CXCL10 production may therefore be a marker of active immune responses against not just M. tuberculosis but also other nonviral pathogens. However, as CXCL10 is produced during both innate and adaptive immune responses,12 it is not possible to determine what type of immune response is being generated.
Equation (Uncited)Image Tools
Data from the FIRST Study13 and a study by Porter et al14 indicated that high pre-ART plasma levels of C-reactive protein and D-dimer identified patients with a high risk of developing IRD and/or an AIDS-defining event. Haddow et al7 also demonstrated higher serum C-reactive protein levels in patients who developed “unmasking TB-IRIS” but did not show a difference in CXCL10 levels from controls. Here, we measured specific markers of immune function and activation. We show that these markers are not predictive of a single type of IRD but pre-ART levels of CXCL10 were elevated in patients who developed a “non-viral IRD,” compared with matched controls.
Equation (Uncited)Image Tools
These findings provide support for our previous suggestions that the immunopathogenesis of IRD may be different for different types of pathogen2 and that markers of immune responses against some pathogens are present before ART is commenced.3,4 We suggest that plasma CXCL10 levels should be assessed as a marker of IRD risk in future studies.
Equation (Uncited)Image Tools
Equation (Uncited)Image Tools
The authors would like to thank the personnel at the Genomic Unit, Centro Nacional de Microbiología, Instituto de Salud Carlos III, for technical assistance in sequencing; Ana Sánchez for processing patients' data; and José Antonio Taboada for his support of this study.
1. French MA. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis. 2009;48:101–107.
2. Price P, Murdoch DM, Agarwal U, et al.. Immune restoration diseases reflect diverse immunopathological mechanisms. Clin Microbiol Rev. 2009;22:651–663.
3. Elliott JH, Vohith K, Saramony S, et al.. Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy. J Infect Dis. 2009;200:1736–1745.
4. Oliver BG, Elliott JH, Price P, et al.. Mediators of innate and adaptive immune responses differentially affect immune restoration disease associated with mycobacterium tuberculosis in HIV patients beginning antiretroviral therapy. J Infect Dis. 2010;202:1728–1737.
5. Boulware DR, Meya DB, Bergemann TL, et al.. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med. 2010;7:e1000384.
6. Sereti I, Rodger AJ, French MA. Biomarkers in immune reconstitution inflammatory syndrome: signals from pathogenesis. Curr Opin HIV AIDS. 2010;5:504–510.
7. Haddow LJ, Dibben O, Moosa MY, et al.. Circulating inflammatory biomarkers can predict and characterize tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2011;25:1163–1174.
8. Yeni P, Cooper DA, Aboulker JP, et al.. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet. 2006;368:287–298.
9. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS. 2004;18:1615–1627.
10. Keane N, Price P, Lee S, et al.. An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy. Clin Exp Immunol. 2001;126:111–116.
11. Crane M, Oliver B, Matthews G, et al.. Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. J Infect Dis. 2009;199:974–981.
12. Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol. 2011;89:207–215.
13. Boulware DR, Hullsiek KH, Puronen CE, et al.. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis. 2011;203:1637–1646.
14. Porter BO, Ouedraogo GL, Hodge JN, et al.. d-Dimer and CRP levels are elevated prior to antiretroviral treatment in patients who develop IRIS. Clin Immunol. 2010;136:42–50.
antiretroviral therapy; CXCL10; human immunodeficiency virus; immune restoration disease; INITIO
© 2012 Lippincott Williams & Wilkins, Inc.